FOXO4-DRI (Proxofim): The D-Retro-Inverso Senolytic Peptide Targeting the FOXO4-p53 Axis

Introduction: The Problem of Cellular Senescence

Cellular senescence — the irreversible arrest of cell proliferation in response to various stressors — has emerged as one of the most actively investigated phenomena in aging and disease research. While senescence initially serves as a protective mechanism against uncontrolled cell division, the progressive accumulation of senescent cells with age creates a paradox: these cells persist in tissues and secrete a complex mixture of pro-inflammatory cytokines, chemokines, growth factors, and proteases collectively termed the senescence-associated secretory phenotype (SASP) (Gorgoulis et al., 2019).

The SASP is not merely a byproduct of cellular arrest. Research has established that it actively disrupts tissue homeostasis, promotes chronic inflammation, and can induce senescence in neighboring cells through paracrine signaling. This cascade has led researchers to investigate whether the selective elimination of senescent cells — a strategy termed "senolysis" — could restore tissue function in experimental models.

Among the emerging class of senolytic compounds, FOXO4-DRI (also known as Proxofim) represents a fundamentally different approach. Rather than targeting the broad anti-apoptotic machinery that keeps senescent cells alive, FOXO4-DRI was rationally designed to disrupt a single, specific protein-protein interaction: the binding of the transcription factor FOXO4 to the tumor suppressor p53. This article provides a comprehensive research overview of FOXO4-DRI, from its molecular design to its expanding investigation across multiple in vitro and in vivo experimental systems.

The FOXO4-p53 Axis in Senescent Cells

Why Senescent Cells Resist Apoptosis

A central question in senescence research is why these damaged cells persist rather than undergoing programmed cell death. Senescent cells upregulate multiple senescence cell anti-apoptotic pathways (SCAPs) involving ephrins, PI3K isoforms, HIF-1α, plasminogen-activated inhibitors, and members of the Bcl-2 protein family. These overlapping survival mechanisms make senescent cells remarkably resistant to apoptotic stimuli.

The FOXO4-p53 interaction represents a distinct survival mechanism. In the seminal 2017 study by Baar and colleagues published in Cell, the research team demonstrated that the forkhead box O4 (FOXO4) transcription factor is selectively upregulated in senescent cells. Upon activation, FOXO4 physically binds to p53 and sequesters it within promyelocytic leukemia (PML) nuclear bodies — specialized nuclear substructures that are hallmarks of the senescent state (Baar et al., 2017).

This sequestration is critical: by trapping p53 in PML nuclear bodies, FOXO4 prevents p53 from translocating to the cytoplasm and mitochondria where it would activate intrinsic apoptotic cascades. In essence, FOXO4 acts as a molecular bodyguard, keeping the cell's own tumor suppressor from triggering self-destruction.

Structural Basis of the Interaction

A 2025 study published in Nature Communications by Bourgeois, de Keizer, and colleagues provided detailed structural characterization of the FOXO4-p53 binding interface. Using nuclear magnetic resonance (NMR) spectroscopy and molecular dynamics simulations, the researchers mapped the interaction to the intrinsically disordered transactivation domain (TAD) of p53. This is significant because the TAD is the same region through which p53 interacts with MDM2 and other regulatory partners (Bourgeois et al., 2025).

The study further revealed that phosphorylation of p53 — a post-translational modification commonly observed in senescent cells — enhances the affinity of p53 for both native FOXO4 and the FOXO4-DRI peptide. This finding has important implications for understanding the selectivity of FOXO4-DRI toward senescent cells, where both FOXO4 upregulation and p53 phosphorylation converge.

FOXO4-DRI: Rational Design of a Senolytic Peptide

The D-Retro-Inverso Strategy

FOXO4-DRI derives its name from the D-retro-inverso (DRI) modification applied to a peptide fragment corresponding to the p53-binding region of FOXO4. The D-retro-inverso approach is an established strategy in peptide chemistry that involves two simultaneous modifications (Gupta et al., 2021):

1. Retro (sequence reversal): The amino acid sequence is reversed from C-to-N terminal direction to N-to-C.

2. Inverso (stereochemical inversion): All L-amino acid residues are replaced with their D-amino acid counterparts.

The combination of these two modifications has a counterintuitive but well-documented effect: the resulting peptide maintains a similar spatial arrangement of amino acid side chains compared to the parent L-peptide, preserving the ability to interact with the same binding partners. However, because proteolytic enzymes are evolved to recognize and cleave peptide bonds between L-amino acid residues, the D-retro-inverso peptide gains dramatically enhanced resistance to enzymatic degradation.

The complete FOXO4-DRI sequence is a 46-amino acid peptide composed entirely of D-amino acid residues in the reversed sequence of the native FOXO4 p53-binding domain. This design provides the peptide with substantially increased metabolic stability compared to a conventional L-amino acid peptide of the same binding specificity.

Mechanism of Senolytic Action

The mechanism by which FOXO4-DRI induces selective apoptosis in senescent cells can be summarized in a stepwise model:

1. Cell penetration: FOXO4-DRI contains a cell-penetrating peptide (CPP) sequence that facilitates its translocation across cell membranes.

2. Competitive binding: Once inside the cell, FOXO4-DRI competes with endogenous FOXO4 for binding to p53. Because the peptide mimics the FOXO4 interaction interface, it disrupts the existing FOXO4-p53 complex in PML nuclear bodies.

3. p53 nuclear exclusion: With the FOXO4-p53 complex disrupted, p53 is released from PML bodies and is no longer sequestered in the nucleus. Freed p53 translocates to the cytoplasm and mitochondria.

4. Intrinsic apoptosis activation: At the mitochondria, p53 activates the intrinsic apoptotic pathway, triggering caspase cascades and ultimately leading to programmed cell death.

The selectivity of this mechanism arises from the biology of senescent cells themselves: FOXO4 is selectively upregulated in senescent cells, and the FOXO4-p53 interaction in PML bodies is a feature specific to the senescent state. In non-senescent (proliferating or quiescent) cells, FOXO4 levels are low and the p53-PML body interaction is not a primary survival mechanism, meaning FOXO4-DRI has a minimal effect.

Key Research Findings Across Experimental Systems

The Original In Vivo Study (2017)

The foundational study by Baar et al. established the senolytic concept of FOXO4-DRI across multiple experimental models. In fast-aging XpdTTD/TTD mice and naturally aged wild-type mice, FOXO4-DRI treatment resulted in the neutralization of doxorubicin-induced chemotoxicity and the restoration of fitness, fur density, and renal function. Critically, the peptide induced selective apoptosis in senescent cells while leaving non-senescent cells unaffected — a key requirement for any viable senolytic strategy (Baar et al., 2017).

The study also demonstrated that FOXO4-DRI was well-tolerated under the experimental conditions used. Unlike the BCL-2 family inhibitors ABT-263 (navitoclax) and ABT-737, which were known to induce severe thrombocytopenia in experimental models, FOXO4-DRI did not exhibit this particular limitation in the reported experiments, though the authors noted that comprehensive toxicological profiling remained to be completed.

Chondrocyte Senescence and Cartilage Research (2021)

Huang et al. investigated FOXO4-DRI in the context of in vitro expanded human chondrocytes — a system directly relevant to autologous chondrocyte implantation (ACI) research. When chondrocytes are expanded in culture for tissue engineering applications, they progressively accumulate senescent cells, which compromises the quality of the resulting cartilage tissue.

Treatment with FOXO4-DRI removed more than half of the cells at high population doubling levels (PDL9, representing extensively passaged cells) while having minimal effect on low-passage (PDL3) chondrocytes with low senescence burden. The senescence level in treated high-passage chondrocytes was significantly reduced compared to untreated controls (Huang et al., 2021).

Reproductive Aging Research (2020)

Zhang et al. examined FOXO4-DRI in the context of age-related changes in Leydig cells using aged mice and hydrogen peroxide-induced senescent TM3 cell models. The researchers demonstrated that FOXO4 maintained the viability of senescent Leydig cells and suppressed their apoptosis. By disrupting the FOXO4-p53 interaction, FOXO4-DRI selectively induced p53 nuclear exclusion and apoptosis in senescent Leydig cells. In vivo treatment of aged mice was associated with reduced senescent cell burden in the testicular interstitium (Zhang et al., 2020).

Keloid Fibroblast Research (2025)

In a study published in Communications Biology, Kong et al. investigated FOXO4-DRI's effects on senescent keloid fibroblasts. The researchers found that FOXO4-DRI induced apoptosis specifically in senescent keloid fibroblasts by promoting nuclear exclusion of p53 phosphorylated at serine 15 (p53-Ser15). This work added mechanistic detail to the understanding of FOXO4-DRI's action, identifying p53-Ser15 phosphorylation as a key event in the senolytic cascade (Kong et al., 2025).

Endothelial Cell Senescence (2025)

Research published in Frontiers in Bioengineering and Biotechnology extended FOXO4-DRI investigation to endothelial cell senescence — a process directly relevant to vascular aging and cardiovascular disease research. The study confirmed that FOXO4-DRI promotes the nuclear export of phosphorylated p53 by inhibiting FOXO4-p53 binding in endothelial cells, facilitating apoptosis of senescent endothelial cells and demonstrating the peptide's activity across yet another cell type and tissue context (FOXO4-DRI and Endothelial Senescence, 2026).

Next-Generation Peptide Design (2021)

Building on the original FOXO4-DRI concept, Le et al. used molecular modeling of the FOXO4-TP53 interaction interface to design rationally optimized senolytic peptides. Their lead compound, designated ES2, demonstrated rapid destruction of TP53-FOXO4 foci and induction of TP53-mediated apoptosis with greater selectivity for senescent cells over proliferating cells in experimental assays. This work established that the FOXO4-p53 disruption strategy could be further refined beyond the original DRI peptide design (Le et al., 2021).

FOXO4-DRI in the Senolytic Research Landscape

Comparison with Other Senolytic Approaches

The senolytic research field has produced several distinct classes of compounds, each targeting different aspects of senescent cell survival:

Dasatinib + Quercetin (D+Q): This combination targets SCAPs including ephrin-dependent survival signaling and PI3K/AKT pathways. D+Q has advanced furthest toward translational research, with Phase I investigations in multiple disease contexts. However, dasatinib was shown to exhibit cell-type-dependent senolytic activity — effective in senescent preadipocytes but not in senescent endothelial cells.

Navitoclax (ABT-263): A pan-BCL-2 family inhibitor that targets the anti-apoptotic proteins BCL-2, BCL-xL, and BCL-w. While potent as a senolytic in certain cell types, navitoclax carries the well-documented limitation of inducing thrombocytopenia due to platelet dependence on BCL-xL for survival.

Fisetin: A naturally occurring flavonoid with senolytic properties attributed to multiple mechanisms. While advantageous from a safety perspective, fisetin generally exhibits lower potency compared to purpose-built senolytic compounds.

FOXO4-DRI: Distinguished by its mechanism of targeting a specific protein-protein interaction (FOXO4-p53) rather than broad signaling pathways or anti-apoptotic protein families. This targeted approach theoretically offers a more favorable selectivity profile, as the mechanism depends on a feature (elevated FOXO4 and p53 co-localization in PML bodies) that is specific to the senescent state. Research from multiple laboratories has now confirmed senolytic activity across diverse cell types including fibroblasts, chondrocytes, Leydig cells, endothelial cells, and keloid fibroblasts.

Current Research Limitations

Several important research considerations remain:

• •Delivery challenges: As a 46-amino acid peptide, FOXO4-DRI faces pharmacokinetic limitations typical of peptide-based research compounds, including limited oral bioavailability and potential for rapid renal clearance. The DRI modification addresses proteolytic degradation but does not fully resolve all delivery challenges.
• •Cell-type dependent responses: While FOXO4-DRI has demonstrated senolytic activity across multiple cell types, the magnitude of effect varies, and not all senescent cell populations have been evaluated.
• •Incomplete toxicological characterization: Comprehensive safety profiling in multiple species and across various experimental parameters remains an active area of investigation.
• •Specificity for senescence subtypes: Senescence can be induced by diverse stimuli (oncogene activation, DNA damage, oxidative stress, replicative exhaustion), and the relative dependence on the FOXO4-p53 axis may vary across senescence subtypes.

Practical Research Considerations

Peptide Handling and Stability

FOXO4-DRI is typically supplied as a lyophilized powder for research use. Key considerations for laboratory handling include:

• •Solubility: The peptide is generally soluble in aqueous buffers at research-relevant concentrations. Due to its arginine-rich cell-penetrating sequence, it is positively charged at physiological pH.
• •Storage: As with most research peptides, lyophilized FOXO4-DRI should be stored at -20°C or below. Once reconstituted, aliquoting and storage at -80°C is recommended to minimize freeze-thaw cycles.
• •Stability advantage: The D-retro-inverso modification confers substantially greater stability compared to L-amino acid peptides of equivalent length, as D-amino acid peptide bonds resist cleavage by endogenous proteases. This is a significant practical advantage in experimental settings where prolonged incubation times are required.

For detailed guidance on peptide preparation, see our Peptide Solubility and Solvent Selection Guide and Peptide Storage Best Practices.

Purity Verification

Given the complexity of a 46-amino acid all-D peptide, researchers should verify the identity and purity of FOXO4-DRI using appropriate analytical methods. High-performance liquid chromatography (HPLC) and mass spectrometry are essential for confirming the correct molecular weight and assessing purity. Chiral analysis may also be warranted to confirm D-amino acid composition, as inadvertent L-amino acid incorporation during synthesis could compromise the proteolytic resistance that is central to the DRI design.

For more on analytical verification, see our guide on Peptide Purity Testing Methods: HPLC and Mass Spectrometry Explained.

The Broader Context: Senolytic Research and Aging

FOXO4-DRI sits at the intersection of several converging research trajectories: the biology of cellular senescence, rational peptide design, and the emerging field of geroscience — the study of biological mechanisms of aging as drivers of age-related diseases. The compound's continued investigation across diverse experimental systems underscores the growing research interest in targeted senolytic strategies.

The progression from the original 2017 discovery to the detailed structural characterization in 2025 and the ongoing expansion into new cell types and tissue contexts illustrates the trajectory typical of a research compound gaining traction. Each new study adds mechanistic depth and broadens the understanding of where and how the FOXO4-p53 axis operates in senescent biology.

For researchers interested in related compounds, our guides on Epitalon and the Anti-Aging Peptides overview provide additional context on peptide-based approaches in aging research.

Summary

FOXO4-DRI represents a rationally designed peptide tool for investigating the role of the FOXO4-p53 interaction in senescent cell survival. Its D-retro-inverso design provides enhanced proteolytic stability while preserving the ability to competitively disrupt FOXO4-p53 binding. Research across multiple independent laboratories has demonstrated selective senolytic activity in diverse cell types, with the mechanism dependent on p53 nuclear exclusion and subsequent activation of intrinsic apoptotic pathways. As one of the few peptide-based senolytics under active investigation, FOXO4-DRI continues to generate significant research interest in the cellular senescence and aging fields.

---

References

1. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. PubMed

2. Zhang C, Xie Y, Chen H, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging. 2020;12(2):1272-1284. PMC

3. Huang Y, He Y, Makarcyzk MJ, Lin H. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021;9:677576. PMC

4. Le HH, Cinaroglu SS, Manalo EC, et al. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. eBioMedicine. 2021;73:103646. PubMed

5. Kong YX, Li ZS, Liu YB, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025;8:299. Nature

6. Bourgeois BRM, Spreitzer E, Platero-Rochart D, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025;16:5929. Nature

7. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Front Bioeng Biotechnol. 2026;13:1729166. PubMed

8. Gupta S, Kapoor P, Chaudhary K, et al. Recent Applications of Retro-Inverso Peptides. Int J Mol Sci. 2021;22(16):8677. PMC

9. Gorgoulis V, Adams PD, Alimonti A, et al. Cellular Senescence: Defining a Path Forward. Cell. 2019;179(4):813-827. PubMed

---

Research Tools

Researchers sourcing this peptide for laboratory investigation can use the peptide price comparison tool to identify research-grade material from verified suppliers. For reconstitution planning, the peptide calculator provides molar mass, concentration, and dilution calculations.

This article is intended for educational and research purposes only. FOXO4-DRI is a research compound sold exclusively for in vitro and laboratory investigation. It is not approved for human or animal use and should not be employed outside of properly supervised research settings. Always consult relevant institutional guidelines and regulatory frameworks before incorporating any research compound into experimental protocols.

FOXO4-DRI Supplier Pricing Comparison (Live Data — 2026)

FOXO4-DRI (Proxofim) is a specialized senolytic research peptide with a targeted supplier market. Peptides.SO tracks listings from dedicated peptide research suppliers.

Price range: $6.90–$350+/mg depending on purity tier and lot size. The specialized nature of senolytic peptide research means fewer mass-market suppliers, but the per-mg cost remains competitive with other complex research peptides.

> Research Use Only. FOXO4-DRI is sold exclusively for laboratory research. Not for human or animal administration.

See the FOXO4-DRI peptide page for real-time pricing and supplier verification data.

Frequently Asked Questions

What makes FOXO4-DRI a "D-retro-inverso" peptide and why does this matter for research?

D-retro-inverso (DRI) peptides are constructed by reversing the amino acid sequence and substituting all L-amino acids with D-amino acids. This creates a mirror-image structure that mimics the bioactive conformation of the original peptide but is highly resistant to proteolytic degradation (since proteases evolved for L-amino acid substrates). For FOXO4-DRI, this design allows the peptide to penetrate cells and engage the FOXO4-p53 interaction site with substantially longer in vivo stability compared to a standard L-amino acid analog. The DRI approach is particularly valuable for intracellular targets like the FOXO4-p53 protein-protein interaction.

How does FOXO4-DRI selectively target senescent cells over healthy cells?

The selectivity mechanism relies on differential FOXO4 expression and localization. In senescent cells, FOXO4 is overexpressed and physically interacts with p53 to sequester it in the nucleus — an active pro-survival signal that prevents senescent cells from undergoing apoptosis. In healthy, non-senescent cells, FOXO4 is expressed at lower levels and does not form this same nuclear p53-retaining complex. FOXO4-DRI disrupts the FOXO4-p53 protein-protein interaction, releasing p53 from nuclear retention. This allows p53 to trigger apoptosis in senescent cells while having minimal effect on the normal p53 lifecycle in healthy cells.

What is the difference between FOXO4-DRI and navitoclax (ABT-263) as senolytics?

Navitoclax targets BCL-2/BCL-xL anti-apoptotic proteins broadly, achieving senolysis but also causing significant platelet depletion (thrombocytopenia) due to BCL-xL dependence in platelets. FOXO4-DRI targets a different node — the FOXO4-p53 interaction specific to cellular senescence — and the 2017 Nature study showed it cleared senescent cells without the platelet toxicity associated with navitoclax. This mechanism specificity is one reason FOXO4-DRI attracted research interest as a potentially safer senolytic approach, though the selectivity profile in different tissue contexts continues to be an area of active investigation.

What cell types and tissues have FOXO4-DRI effects been studied in?

The foundational Baar et al. (2017) study demonstrated FOXO4-DRI activity in: naturally aged mice (clearing p21/p16-positive senescent cells in liver, kidney, and gut), fast-aged chemotherapy mice (doxorubicin model), and progeroid mice (P31T ERCC1 model). Effects included improved physical activity, fur density restoration, and enhanced kidney function. Subsequent research has examined FOXO4-DRI in metabolic disease models (adipose tissue senescence), neuroscience (CNS senescent microglia and astrocytes), and oncology (chemotherapy-induced senescence clearance). The specific tissue distribution and cell type preferences remain areas of active preclinical research.

Are there risks of FOXO4-DRI disrupting normal cell populations?

This is an active research question. The proposed selectivity stems from the elevated FOXO4-p53 interaction in senescent cells, but FOXO4 is also expressed in some normal cell populations. In vitro studies showed no cytotoxicity in normal human fibroblasts, and in vivo studies showed no signs of general toxicity in aged mice. However, long-term effects, species-specific differences, and context-dependent FOXO4 expression patterns in different tissues remain areas of investigation. All FOXO4-DRI research is preclinical.

How does FOXO4-DRI relate to the "two-hit" model of senescence clearance?

Current senolytic research explores the concept that removing senescent cells requires both impairing the SASP-protective cell survival pathways AND triggering apoptosis. FOXO4-DRI addresses the second component by releasing p53 from nuclear sequestration, enabling apoptotic gene transcription. Some research groups have explored combining FOXO4-DRI with quercetin/dasatinib (which address Bcl-2 survival pathways) as a complementary approach, though all such combination studies remain in preclinical stages.

Key Research Citations

1. Baar MP, et al. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell, 169(1):132-147.e16. PMID: 28340339

2. Demaria M, et al. (2017). An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell, 31(6):722-733. PMID: 25499914

---

---

Supplier Pricing: FOXO4-DRI (Proxofim) Research Compounds 2026

Live data from the Peptides.SO database. FOXO4-DRI commands premium pricing relative to most research peptides, reflecting its D-amino acid composition and high-complexity synthesis:

> FOXO4-DRI is a high-value research compound due to its D-retro-inverso amino acid composition requiring specialized synthesis. Price variance across suppliers reflects differences in synthesis scale, purity verification protocols, and supplier overhead. View live pricing at the FOXO4-DRI compare page.

---

Frequently Asked Questions

What makes FOXO4-DRI's D-retro-inverso configuration research-significant?

The D-retro-inverso modification gives FOXO4-DRI proteolytic stability absent in natural L-amino acid peptides. Natural peptides are rapidly degraded by endogenous proteases; the reversed backbone and D-amino acid configuration maintains binding geometry (mimicking the FOXO4 α-helical BH3-like domain) while resisting enzymatic cleavage. This extends in vivo half-life from minutes (for natural peptides) to hours, making the compound practical for preclinical duration studies that natural-sequence FOXO4 peptides cannot achieve.

What distinguishes FOXO4-DRI from the quercetin/dasatinib senolytic combination?

Quercetin/dasatinib (D+Q) inhibit Bcl-2/Bcl-xL pro-survival signaling in senescent cells — interfering with the upstream survival pathway. FOXO4-DRI operates downstream: it disrupts the FOXO4-p53 protein-protein interaction in the nucleus, releasing p53 to activate pro-apoptotic gene transcription (Puma, Bax). These are mechanistically complementary approaches, which has driven preclinical research into potential combination strategies. The selectivity mechanism is also distinct: D+Q target broadly the Bcl-2 family (relevant across multiple cell types), while FOXO4-DRI's proposed selectivity is contingent on elevated nuclear FOXO4-p53 interaction, which has been shown to be specifically upregulated in senescent cells relative to quiescent or cycling populations.

What species of senescent cells does FOXO4-DRI research prioritize?

The foundational Baar et al. (2017) Cell paper demonstrated clearance of p21+ and p16+ senescent cells across liver, kidney, and gut tissue in aged mice and chemotherapy-induced (doxorubicin) models. Subsequent research has expanded to adipose tissue senescent preadipocytes (relevant to metabolic aging), CNS senescent microglia and astrocytes (neuroinflammation context), and chemotherapy-induced senescent cancer cells (evaluating senostatic vs senolytic approaches in tumor microenvironments). Cardiac senescence models are also represented in the literature.

How should researchers evaluate FOXO4-DRI purity given its synthesis complexity?

D-retro-inverso peptides require HPLC purity confirmation specifically — standard amino acid analysis may not distinguish proper backbone inversion. Researchers should look for: mass spectrometry confirmation of molecular weight (MW ~3,745 Da for FOXO4-DRI), HPLC purity ≥98% by peak area, and ideally chiral purity confirmation (verifying D-amino acid incorporation). The pricing premium for this compound partially reflects the analytical burden of quality verification; lowest-cost suppliers may not have invested in the chiral analysis required to confirm proper D-amino acid synthesis.

What in vitro models are most established for FOXO4-DRI research?

IMR-90 human lung fibroblasts (stress-induced senescence model), WI-38 fibroblasts, and MEF (mouse embryonic fibroblast) senescence models are commonly used. Key readouts include: p21/p16 marker downregulation, cleaved caspase-3 activation (apoptosis confirmation), γH2AX colocalization (DNA damage marker in senescent cells), SASP cytokine reduction (IL-6, IL-8 secretion), and β-galactosidase staining (morphological senescence indicator). The Baar et al. protocol used co-culture systems to confirm specificity — FOXO4-DRI induced apoptosis in senescent cells but not in adjacent cycling or quiescent normal fibroblasts.

Further Reading:

• •Humanin: The Mitochondrial-Derived Peptide Redefining Cytoprotection Research
• •Adipotide (FTPP): Complete Research Profile — Prohibitin-Targeting Proapoptotic Peptide for Adipose Vasculature Research
• •Apelin Peptides and the APJ Receptor: The Apelinergic System in Cardiovascular, Metabolic, and Aging Research
• •Reconstitution Calculator
• •Peptide Stack Builder

---

FOXO4-DRI (Proxofim) Supplier Market (2026-09-04)

FOXO4-DRI availability for senolytic research:

• •Active suppliers: 37 vendors
• •In-stock listings: 41
• •Price range: $0.00–$1125.00/mg
• •Market note: Specialized senolytic; smaller supplier pool than commodity peptides

FOXO4-DRI remains a research-focused compound with limited clinical translation. Sourcing is feasible for academic and biotech researchers but requires institutional verification.

---

FOXO4-DRI Senolytic Research: Sourcing & Experimental Design

Q1: What is FOXO4-DRI and why study senescent cells?

A: FOXO4-DRI is a D-retro-inverso peptide that disrupts FOXO4-p53 interaction in senescent cells, triggering senolytic (senescent-cell killing) effects. Senolytics are important for aging and age-related disease models. See FOXO4-DRI: The D-Retro-Inverso Senolytic Peptide for detailed mechanism.

Q2: Is FOXO4-DRI commercially available for research?

A: Yes—37 suppliers carry FOXO4-DRI for research use. Most require institutional affiliation. Smaller supplier pool (37 vs. 94 for BPC-157) reflects its specialized mechanism and research-only status. Availability is strong enough for academic institutions; biotech should have no sourcing issues.

Q3: How does FOXO4-DRI compare to other senolytics (dasatinib, fisetin, quercetin)?

A:

• •FOXO4-DRI: Peptide-based; direct p53 inhibition; high specificity but requires injection
• •Dasatinib: Small-molecule kinase inhibitor; broad activity; oral bioavailability
• •Fisetin/Quercetin: Plant polyphenols; mild senolytic activity; oral; low specificity

For mechanistic senolytic research, FOXO4-DRI is preferred. For applied studies, small-molecule senolytics offer better pharmacokinetics.

Q4: What dose should I use for FOXO4-DRI in senescence models?

A: Typical protocol: 5–10 mg/kg, administered via IP injection or IV, once or twice weekly. Efficacy windows (when senescent cells accumulate) vary by model. Consult published protocols for your specific tissue/disease model (e.g., lung fibrosis, cardiac aging, neurodegeneration).

Q5: Can I use FOXO4-DRI in combination with other senolytics?

A: Yes. Combining FOXO4-DRI with other mechanisms (e.g., dasatinib + quercetin + FOXO4-DRI) is an active research area. Verify combinatorial toxicity and efficacy endpoints before co-dosing. Literature is emerging on multi-senolytic approaches.

Q6: How stable is FOXO4-DRI in storage and reconstitution?

A: Good stability:

• •Lyophilized: 1–2 years at -20°C (peptides more stable than small molecules)
• •Reconstituted: 1–2 weeks at 4°C in PBS
• •Freeze-thaw: Moderate tolerance; minimize cycles

D-retro-inverso peptides are more stable than L-peptides due to D-amino acid stereochemistry. Longer storage than expected for typical peptides.

Q7: Why is FOXO4-DRI pricing varied ($0.00–$1125.00/mg)?

A: Price variance reflects:

1. Supplier tier: Tier 1 (pharmaceutical-grade, ISO accredited) vs. Tier 3 (research commodity)

2. Purity: D-retro-inverso synthesis requires HPLC >95%–99%; high-purity carries premium

3. Quantity: Bulk orders (>1g) may discount significantly

4. Manufacturing: D-retro-inverso synthesis is more complex than L-peptides

Budget researchers should request mid-tier suppliers ($20–50/mg) with verified HPLC data.

Q8: Is FOXO4-DRI the only D-retro-inverso senolytic available?

A: Currently, FOXO4-DRI is the most established D-retro-inverso senolytic. Related compounds are in development. For now, FOXO4-DRI is the primary option for targeted FOXO4-p53 senolytic research. See Senolytic Peptides & Compounds for updates on emerging senolytics.